Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out
Source: SeekingAlpha
2026-04-28 11:27:33 ET
The recent collapse of Replimune’s lead program has, in the most definitive sense, cleared the competitive runway for Iovance Biotherapeutics (IOVA) in the short term, reinforcing its dominant position in the post-PD-1 melanoma market. Indeed, as of April 10, 2026, the FDA issued a second and final Complete Response Letter ( CRL ) to Replimune for its oncolytic virus, RP1 (vusolimogene oderparepvec), in combination with nivolumab....
Read the full article on Seeking Alpha
For further details see:
Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
28.78% G/L:
$5.19 Last:
9,599,164 Volume:
$3.99 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
